Sign in
4

Changes in Ownership

Oncotelic Therapeutics, Inc. Filed Acc 0001209191-18-039169

Options or other derivatives

  • Chief Financial Officer acquired 750,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
LOAR MATTHEW M Chief Financial Officer 2018-06-20 Grant or award · Employee Stock Option (Right to Buy) +250,000 250,000 D
LOAR MATTHEW M Chief Financial Officer 2018-06-20 Grant or award · Employee Stock Option (Right to Buy) +500,000 500,000 D
Loading xslF345X03/doc4.xml…